ALX2004 and evorpacept on track for phase III readiness by mid-2025
ALX2004 is advancing through dose escalation toward proof-of-concept in key tumor types by mid-2025. Evorpacept, a biomarker-driven CD47-high cancer program, targets phase III readiness next year.